TWO · 6483.TWO
Original BioMedicals Co., Ltd.
NT$14.60-NT$0.35 (-2.34%)
Original BioMedicals Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 27.0% below the high.
Loading market information…
TWO · 6615.TWO · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:14 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Sofiva Genomics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 17.25% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Sofiva Genomics Co.,Ltd.’s forward annual dividend is NT$0.30 per share, paid annual. The forward yield is 0.91% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Sofiva Genomics Co.,Ltd.’s next earnings report is currently expected on Nov 18, 2026, with estimated earnings per share of NT$0.71. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sofiva Genomics Co.,Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Sofiva Genomics Co.,Ltd., established in 2012 and based in Taipei, Taiwan, offers a comprehensive range of genetic testing services to both domestic and international clients. The company's diverse diagnostic solutions are designed to support expectant parents, individuals with inherited conditions, and their families. Their extensive prenatal diagnostics include screenings for conditions such as thalassemia carrier status, various microdeletion syndromes, single-gene abnormalities, common chromosomal anomalies, and specific skeletal dysplasia mutations. They also provide multi-gene panel testing for inherited diseases, folate metabolism genetic analysis, carrier screening for spinal muscular atrophy (SMA) and Fragile X syndrome, congenital infection detection, preeclampsia risk assessment, maternal serum screening for Down syndrome, and karyotyping. Within the oncology sector, Sofiva Genomics delivers advanced cancer screenings, dynamic monitoring of tumor activity, and genetic evaluations for hereditary cancer predisposition. This includes specialized panels for women's cancers (breast, colon, ovarian, and endometrial), alongside human papillomavirus (HPV) screening. Furthermore, the company conducts genetic testing for rare diseases and provides specialized reproductive services such as preimplantation genetic diagnosis (PGD) and next-generation sequencing (NGS)-based preimplantation genetic screening (PGS). For newborns, their services encompass comprehensive "baby scans," screenings for hereditary sensorineural hearing loss, congenital central hypoventilation syndrome (CCHS), congenital cytomegalovirus (CMV) infection, and genetic risk assessment for atopic dermatitis. Beyond these specialized offerings, Sofiva Genomics also performs biochemical and chromosomal analyses, complemented by valuable advisory and support services for its clientele.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:43 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q3 2024 | Nov 13, 2024 | NT$0.08 | NT$106.25M |
|---|
| Q2 2024 | Aug 14, 2024 | NT$0.45-37.5% vs estimate | NT$122.57M-9.88% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$14.60-NT$0.35 (-2.34%)
Original BioMedicals Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 27.0% below the high.
NT$15.40-NT$0.65 (-4.05%)
AmCad BioMed Corporation’s quoted price sits in the upper half of its reported 52-week range, 18.3% below the high.
NT$18.65NT$0.00 (0.0%)
TFBS Bioscience Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.03% below the high.
NT$18.05+NT$0.05 (+0.28%)
EBM Technologies Incorporated’s quoted price sits in the lower half of its reported 52-week range, 27.66% below the high.
NT$6.79-NT$0.04 (-0.59%)
TaiwanJ Pharmaceuticals Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 30.71% below the high.
NT$12.00NT$0.00 (0.0%)
Vectorite Biomedical Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.88% below the high.
NT$17.25-NT$0.60 (-3.36%)
Bioray Biotech Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 33.91% below the high.
NT$9.72+NT$0.15 (+1.57%)
Health & Life Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 32.97% below the high.
